Diligence memo · auto-generated · as of July 2, 2026

Zena Therapeutics Inc.

Zena Therapeutics Inc. looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Zena Therapeutics Inc. operates in Pharmaceuticals, based in PRINCETON.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Zena Therapeutics Inc. has raised $500K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $500K on 2023-08-11.

Most recent recorded round closed around 2023-08-11.

Valuation (modeled)modeled

Provath models Zena Therapeutics Inc. at approximately $3.8M (range $280K–$17M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.50× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Within the normal band (150% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 2.9 yr ago; this sector typically re-raises about every 13 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

Comparablesmixed

Capital scale ranks ahead of 13% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 7% of those peers.

Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.